Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Pfizer

Status: Completed

Conditions: Macular Degeneration

Treatments: Drug: Pegaptanib sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT00845273

A5751033

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first Macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 3,538 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered Macugen® in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered Macugen®.

Trial design

3,538 participants in 1 patient group

Pegaptanib sodium

Description:

Patients administered Pegaptanib sodium.

Treatment:

Drug: Pegaptanib sodium